Activation of FoxO1/SIRT1/RANKL/OPG pathway may underlie the therapeutic effects of resveratrol on aging-dependent male osteoporosis

BACKGROUND: Age-dependent male osteoporosis remains a poorly studied medical problem despite its significance. It is estimated that at least 1 of 5 men will suffer from osteoporotic consequences. Given that multiple mechanisms are involved in the process of senescence, much attention has been given to compounds with polymodal actions. To challenge such a health problem, we tested here the therapeutic potential of resveratrol in male osteoporosis. We also studied the possible molecular mechanisms that may underlie resveratrol effects.

METHODS: Thirty male Wistar albino rats were used in the present study. Rats were divided (10/group) into: control (3-4 months old weighing 150-200 g receiving vehicle), aged (18-20 months old, weighing 350-400 g and receiving vehicle), and resveratrol treated aged (18-20 months old, weighing 350-400 g and receiving resveratrol 20 mg/kg/day for 6 weeks) groups. Assessment of serum calcium, phosphate, bone specific alkaline phosphatase, inflammatory cytokines, oxidative stress markers, and rat femur gene expression of FoxO1, SIRT1, RANKL and OPG proteins was carried out. Histopathological assessment of different levels of rat femur was also performed.

RESULTS: Age-dependent osteoporosis resulted in significant increase in serum levels of phosphate, bone specific alkaline phosphatase, hsCRP, IL-1β, IL-6, TNF-α, MDA, NO, and RANKL gene expression. However, there was significant decrease in serum level of GSH, and gene expression of FoxO1, SIRT1 and OPG. Osteoporotic changes were seen in femur epiphysis, metaphysis and diaphysis. Resveratrol restored significantly age-dependent osteoporotic changes.

CONCLUSION: We concluded that resveratrol can play an important role in the prevention of male osteoporosis. Resveratrol can counter the molecular changes in male osteoporosis via anti-inflammatory, anti-oxidant and gene modifying effects.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:21

Enthalten in:

BMC musculoskeletal disorders - 21(2020), 1 vom: 12. Juni, Seite 375

Sprache:

Englisch

Beteiligte Personen:

Ameen, Omnia [VerfasserIn]
Yassien, Rania I [VerfasserIn]
Naguib, Yahya M [VerfasserIn]

Links:

Volltext

Themen:

Aging
Antioxidants
Cytokines
EC 3.5.1.-
FoxO1
Foxo1 protein, rat
Journal Article
Male osteoporosois
Nerve Tissue Proteins
OPG
Osteoprotegerin
Q369O8926L
RANK Ligand
RANKL
Resveratrol
SIRT1
Sirt1 protein, rat
Sirtuin 1
Type II osteoporosis

Anmerkungen:

Date Completed 15.03.2021

Date Revised 07.12.2022

published: Electronic

Citation Status MEDLINE

doi:

10.1186/s12891-020-03389-w

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM311113850